Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2013 2
2018 1
2019 1
2020 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
Matsumoto C, Ogawa H, Saito Y, Okada S, Soejima H, Sakuma M, Masuda I, Nakayama M, Doi N, Jinnouchi H, Waki M, Morimoto T; JPAD Trial Investigators; JPAD Trial Investigators:. Matsumoto C, et al. Diabetes Care. 2020 Feb;43(2):314-320. doi: 10.2337/dc19-1188. Epub 2019 Dec 4. Diabetes Care. 2020. PMID: 31801787 Clinical Trial.
Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.
Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, Sugiyama S, Jinnouchi H, Waki M, Doi N, Horii M, Kawata H, Somekawa S, Soeda T, Uemura S, Saito Y; investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Okada S, et al. Circ J. 2013;77(12):3023-8. doi: 10.1253/circj.cj-13-0307. Epub 2013 Sep 13. Circ J. 2013. PMID: 24042256 Free article. Clinical Trial.
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Saito Y, et al. Diabetes Care. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615. Diabetes Care. 2011. PMID: 21270185 Free PMC article. Clinical Trial.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Ogawa H, et al. JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. JAMA. 2008. PMID: 18997198 Clinical Trial.
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Sakuma M, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators. Soejima H, et al. J Cardiol. 2013 Sep;62(3):165-70. doi: 10.1016/j.jjcc.2013.03.015. Epub 2013 Jun 16. J Cardiol. 2013. PMID: 23778008 Free article. Clinical Trial.